Table Info

Table 2.

Summary of the major compounds targeting Ca²⁺ channels/pumps/exchangers in lung cancer progression

Ca²⁺ channel/pump/exchanger	Drug Candidates	Pharmacological effects
TRPCs	SKF-96365	Cell cycle arrest at S/G2M phase, and invasive ability in A549 cell line [130]
	ATRA 2-ABP	Proliferative inhibition in A549 cells line [131]
	Carvacrol	Degeneration of cell morphology, and apoptosis in A549 cell line [132, 133]
	Capsaicin	Apoptosis in SCLC cell lines, NCI-H82, NCI-H69 [134]
	Tetrahydrocannabinol and cannabidiol	Inhibition of proliferation, epithelial-mesenchymal transition (EMT) and migration in A549, H460 and H1792 lung cancer cell lines [135]
	Dexamethasone	Growth suppression in NSCLC cell lines, A549 and H1299 [136]
RyR	Compound K	ER-mediated apoptosis in A549 and SK-MES-1 cell lines [137]
RyR	Paclitaxel	Cell cycle arrest at G2/M phase in A549 cell line [138]
IP₃R3	Α-Lipoic acid (LA)	Apoptosis in A549 cell line [139]
IP₃R3	Curcumin	Apoptosis in NSCLC cell lines, A549 and H1299 [140]
VGCCs	Verapamil, Diltiazem, and Nifepine	Cell death in chemoresistant lung cancer cells derived from A549 cell line [141]
SERCA	2-deoxy D-glucose and metformin	Apoptosis in A549 cell line [142]
Voltage-dependent anion channel (VDAC)	R-Tf-D-LP4	Apoptosis and inhibition of tumor growth HepG2 and Huh-7 cell lines [143]

Declarations

Author contributions

The author contributed solely to the work.

Conflicts of interest

The author declares that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Cui C, Merritt R, Fu L, Pan Z. Targeting calcium signaling in cancer therapy. Acta Pharm Sin B. 2017;7:3–17. [DOI]

Islam MS. Calcium signaling: from basic to bedside. Adv Exp Med Biol. 2020;1131:1–6. [DOI] [PubMed]

Pchitskaya E, Popugaeva E, Bezprozvanny I. Calcium signaling and molecular mechanisms underlying neurodegenerative diseases. Cell Calcium. 2018;70:87–94. [DOI] [PubMed] [PMC]

Yoshikawa F, Morita M, Monkawa T, Michikawa T, Furuichi T, Mikoshiba K. Mutational analysis of the ligand binding site of the inositol 1,4,5-trisphosphate receptor. J Biol Chem. 1996;271:18277–84. [DOI] [PubMed]

Dulhunty AF, Board PG, Beard NA, Casarotto MG. Physiology and pharmacology of ryanodine receptor calcium release channels. Adv Pharmacol. 2017;79:287–324. [DOI] [PubMed]

Kania E, Roest G, Vervliet T, Parys JB, Bultynck G. IP3 receptor-mediated calcium signaling and its role in autophagy in cancer. Front Oncol. 2017;7:140. [DOI] [PubMed] [PMC]

Di Leva F, Domi T, Fedrizzi L, Lim D, Carafoli E. The plasma membrane Ca²⁺ ATPase of animal cells: structure, function and regulation. Arch Biochem Biophys. 2008;476:65–74. [DOI] [PubMed]

Reppel M, Fleischmann BK, Reuter H, Sasse P, Schunkert H, Hescheler J. Regulation of the Na⁺/Ca²⁺ exchanger (NCX) in the murine embryonic heart. Cardiovasc Res. 2007;75:99–108. [DOI] [PubMed]

Primeau JO, Armanious GP, Fisher ME, Young HS. The sarcoendoplasmic reticulum calcium ATPase. Subcell Biochem. 2018;87:229–58. [DOI] [PubMed]

10.

Dong N, Shi L, Wang DC, Chen C, Wang X. Role of epigenetics in lung cancer heterogeneity and clinical implication. Semin Cell Dev Biol. 2017;64:18–25. [DOI] [PubMed]

11.

Zhou Y, Yu QF, Peng AF, Tong WL, Liu JM, Liu ZL. The risk factors of bone metastases in patients with lung cancer. Sci Rep. 2017;7:8970. [DOI] [PubMed] [PMC]

12.

Reddi AH, Roodman D, Freeman C, Mohla S. Mechanisms of tumor metastasis to the bone: challenges and opportunities. J Bone Miner Res. 2003;18:190–4. [DOI] [PubMed]

13.

Atkinson EG, Delgado-Calle J. The emerging role of osteocytes in cancer in bone. JBMR Plus. 2019;3:e10186. [DOI] [PubMed] [PMC]

14.

Permyakov EA, Kretsinger RH. Cell signaling, beyond cytosolic calcium in eukaryotes. J Inorg Biochem. 2009;103:77–86. [DOI] [PubMed]

15.

Pande G, Kumar NA, Manogaran PS. Flow cytometric study of changes in the intracellular free calcium during the cell cycle. Cytometry. 1996;24:55–63. [DOI] [PubMed]

16.

Elangovan IM, Vaz M, Tamatam CR, Potteti HR, Reddy NM, Reddy SP. FOSL1 promotes kras-induced lung cancer through amphiregulin and cell survival gene regulation. Am J Respir Cell Mol Biol. 2018;58:625–35. [DOI] [PubMed] [PMC]

17.

Huang H, Weng H, Zhou H, Qu L. Attacking c-Myc: targeted and combined therapies for cancer. Curr Pharm Des. 2014;20:6543–54. [DOI] [PubMed]

18.

Hernández S, Hernández L, Beà S, Cazorla M, Fernández PL, Nadal A, et al. cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin’s lymphomas. Cancer Res. 1998;58:1762–7. [PubMed]

19.

Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt’s lymphoma cells. Proc Natl Acad Sci U S A. 2003;100:8164–9. [DOI] [PubMed] [PMC]

20.

Orian A, van Steensel B, Delrow J, Bussemaker HJ, Li L, Sawado T, et al. Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. Genes Dev. 2003;17:1101–14. [DOI] [PubMed] [PMC]

21.

Zhang Y, Zhang A, Shen C, Zhang B, Rao Z, Wang R, et al. E2F1 acts as a negative feedback regulator of c-Myc-induced hTERT transcription during tumorigenesis. Oncol Rep. 2014;32:1273–80. [DOI] [PubMed]

22.

Zheng L, Suzuki H, Nakajo Y, Nakano A, Kato M. Regulation of c-MYC transcriptional activity by transforming growth factor-beta 1-stimulated clone 22. Cancer Sci. 2018;109:395–402. [DOI] [PubMed] [PMC]

23.

Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, et al. Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer. Clin Cancer Res. 2020;26:439–49. [DOI] [PubMed] [PMC]

24.

Pradhan R, Singhvi G, Dubey SK, Gupta G, Dua K. MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma. Future Med Chem. 2019;11:793–5. [DOI] [PubMed]

25.

Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130–46. [DOI] [PubMed] [PMC]

26.

Choi YJ, Anders L. Signaling through cyclin D-dependent kinases. Oncogene. 2014;33:1890–903. [DOI] [PubMed]

27.

Fu H, Gao H, Qi X, Zhao L, Wu D, Bai Y, et al. Aldolase A promotes proliferation and G1/S transition via the EGFR/MAPK pathway in non-small cell lung cancer. Cancer Commun (Lond). 2018;38:18. [DOI] [PubMed] [PMC]

28.

Goodrich DW. The retinoblastoma tumor-suppressor gene, the exception that proves the rule. Oncogene. 2006;25:5233–43. [DOI] [PubMed] [PMC]

29.

Knudsen ES, Pruitt SC, Hershberger PA, Witkiewicz AK, Goodrich DW. Cell cycle and beyond: exploiting new RB1 controlled mechanisms for cancer therapy. Trends Cancer. 2019;5:308–24. [DOI] [PubMed] [PMC]

30.

Sherr CJ. D-type cyclins. Trends Biochem Sci. 1995;20:187–90. [DOI] [PubMed]

31.

Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 2016;6:353–67. [DOI] [PubMed] [PMC]

32.

Zhou YL, Xu YJ, Qiao CW. MiR-34c-3p suppresses the proliferation and invasion of non-small cell lung cancer (NSCLC) by inhibiting PAC1/MAPK pathway. Int J Clin Exp Pathol. 2015;8:6312–22. [PubMed] [PMC]

33.

Gupta R, Dastane AM, Forozan F, Riley-Portuguez A, Chung F, Lopategui J, et al. Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Mod Pathol. 2009;22:128–33. [DOI] [PubMed]

34.

Goshima T, Habara M, Maeda K, Hanaki S, Kato Y, Shimada M. Calcineurin regulates cyclin D1 stability through dephosphorylation at T286. Scientific Reports. 2019;9:12779. [DOI] [PubMed] [PMC]

35.

Liu Y, Zhang Y, Min J, Liu LL, Ma NQ, Feng YM, et al. Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer. Tumour Biol. 2010;31:199–207. [DOI] [PubMed]

36.

Oetjen E, Thoms KM, Laufer Y, Pape D, Blume R, Li P, et al. The immunosuppressive drugs cyclosporin A and tacrolimus inhibit membrane depolarization-induced CREB transcriptional activity at the coactivator level. Br J Pharmacol. 2005;144:982–93. [DOI] [PubMed] [PMC]

37.

Zhang Y, Baumgrass R, Schutkowski M, Fischer G. Branches on the alpha-C atom of cyclosporin A residue 3 result in direct calcineurin inhibition and rapid cyclophilin 18 binding. Chembiochem. 2004;5:1006–9. [DOI] [PubMed]

38.

Chang KT, Berg DK. Voltage-gated channels block nicotinic regulation of CREB phosphorylation and gene expression in neurons. Neuron. 2001;32:855–65. [DOI] [PubMed]

39.

Kahl CR, Means AR. Calcineurin regulates cyclin D1 accumulation in growth-stimulated fibroblasts. Mol Biol Cell. 2004;15:1833–42. [DOI] [PubMed] [PMC]

40.

Tomono M, Toyoshima K, Ito M, Amano H, Kiss Z. Inhibitors of calcineurin block expression of cyclins A and E induced by fibroblast growth factor in Swiss 3T3 fibroblasts. Arch Biochem Biophys. 1998;353:374–8. [DOI] [PubMed]

41.

Feske S, Rao A, Hogan PG. The Ca²⁺-calcineurin-NFAT signalling pathway. In: New Comprehensive Biochemistry. Amsterdam: Elsevier; 2007.p.365–401.

42.

Ay AS, Benzerdjeb N, Sevestre H, Ahidouch A, Ouadid-Ahidouch H. Orai3 constitutes a native store-operated calcium entry that regulates non small cell lung adenocarcinoma cell proliferation. PLoS One. 2013;8:e72889. [DOI] [PubMed] [PMC]

43.

Faouzi M, Kischel P, Hague F, Ahidouch A, Benzerdjeb N, Sevestre H, et al. ORAI3 silencing alters cell proliferation and cell cycle progression via c-myc pathway in breast cancer cells. Biochim Biophys Acta. 2013;1833:752–60. [DOI] [PubMed]

44.

Hou MF, Kuo HC, Li JH, Wang YS, Chang CC, Chen KC, et al. Orai1/CRACM1 overexpression suppresses cell proliferation via attenuation of the store-operated calcium influx-mediated signalling pathway in A549 lung cancer cells. Biochim Biophys Acta. 2011;1810:1278–84. [DOI] [PubMed]

45.

Waite JC, Vardhana S, Shaw PJ, Jang JE, McCarl CA, Cameron TO, et al. Interference with Ca²⁺ release activated Ca²⁺ (CRAC) channel function delays T-cell arrest in vivo. Eur J Immunol. 2013;43:3343–54. [DOI] [PubMed] [PMC]

46.

Harraz OF, Altier C. STIM1-mediated bidirectional regulation of Ca²⁺ entry through voltage-gated calcium channels (VGCC) and calcium-release activated channels (CRAC). Front Cell Neurosci. 2014;8:43. [DOI] [PubMed] [PMC]

47.

Lunz V, Romanin C, Frischauf I. STIM1 activation of Orai1. Cell Calcium. 2019;77:29–38. [DOI] [PubMed]

48.

Park CY, Shcheglovitov A, Dolmetsch R. The CRAC channel activator STIM1 binds and inhibits L-type voltage-gated calcium channels. Science. 2010;330:101–5. [DOI] [PubMed]

49.

Wang Y, Wang H, Li L, Li J, Pan T, Zhang D, et al. Elevated expression of STIM1 is involved in lung tumorigenesis. Oncotarget. 2016;7:86584–93. [DOI] [PubMed] [PMC]

50.

Ge C, Zeng B, Li R, Li Z, Fu Q, Wang W, et al. Knockdown of STIM1 expression inhibits non-small-cell lung cancer cell proliferation in vitro and in nude mouse xenografts. Bioengineered. 2019;10:425–36. [DOI] [PubMed] [PMC]

51.

Roderick HL, Cook SJ. Ca²⁺ signalling checkpoints in cancer: remodelling Ca²⁺ for cancer cell proliferation and survival. Nat Rev Cancer. 2008;8:361–75. [DOI] [PubMed]

52.

Williams CL, Phelps SH, Porter RA. Expression of Ca²⁺/calmodulin-dependent protein kinase types II and IV, and reduced DNA synthesis due to the Ca²⁺/calmodulin-dependent protein kinase inhibitor KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenyl piperazine) in small cell lung carcinoma. Biochem Pharmacol. 1996;51:707–15. [DOI] [PubMed]

53.

Hamada K, Miyatake H, Terauchi A, Mikoshiba K. IP₃-mediated gating mechanism of the IP(3) receptor revealed by mutagenesis and X-ray crystallography. Proc Natl Acad Sci U S A. 2017;114:4661–6. [DOI] [PubMed] [PMC]

54.

Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9:231–41. [DOI] [PubMed]

55.

Reed JC. Apoptosis mechanisms: implications for cancer drug discovery. Oncology (Williston Park). 2004;18:11–20. [PubMed]

56.

Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003;4:552–65. [DOI] [PubMed]

57.

Rimessi A, Bonora M, Marchi S, Patergnani S, Marobbio CM, Lasorsa FM, et al. Perturbed mitochondrial Ca²⁺ signals as causes or consequences of mitophagy induction. Autophagy. 2013;9:1677–86. [DOI] [PubMed]

58.

Arnoult D, Gaume B, Karbowski M, Sharpe JC, Cecconi F, Youle RJ. Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization. EMBO J. 2003;22:4385–99. [DOI] [PubMed] [PMC]

59.

Liu J, Yoshikawa H, Nakajima Y, Tasaka K. Involvement of mitochondrial permeability transition and caspase-9 activation in dimethyl sulfoxide-induced apoptosis of EL-4 lymphoma cells. Int Immunopharmacol. 2001;1:63–74. [DOI] [PubMed]

60.

Petronilli V, Penzo D, Scorrano L, Bernardi P, Di Lisa F. The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings in situ. J Biol Chem. 2001;276:12030–4. [DOI] [PubMed]

61.

Zhou LL, Zhou LY, Luo KQ, Chang DC. Smac/DIABLO and cytochrome c are released from mitochondria through a similar mechanism during UV-induced apoptosis. Apoptosis. 2005;10:289–99. [DOI] [PubMed]

62.

Kerkhofs M, Bittremieux M, Morciano G, Giorgi C, Pinton P, Parys JB, et al. Emerging molecular mechanisms in chemotherapy: Ca²⁺ signaling at the mitochondria-associated endoplasmic reticulum membranes. Cell Death Dis. 2018;9:334. [DOI] [PubMed] [PMC]

63.

Missiroli S, Danese A, Iannitti T, Patergnani S, Perrone M, Previati M, et al. Endoplasmic reticulum-mitochondria Ca²⁺ crosstalk in the control of the tumor cell fate. Biochim Biophys Acta Mol Cell Res. 2017;1864:858–64. [DOI] [PubMed]

64.

D’Orsi B, Mateyka J, Prehn JHM. Control of mitochondrial physiology and cell death by the Bcl-2 family proteins Bax and Bok. Neurochem Int. 2017;109:162–70. [DOI] [PubMed]

65.

Vervliet T, Clerix E, Seitaj B, Ivanova H, Monaco G, Bultynck G. Modulation of Ca²⁺ signaling by anti-apoptotic B-cell lymphoma 2 proteins at the endoplasmic reticulum-mitochondrial interface. Front Oncol. 2017;7:75. [DOI] [PubMed] [PMC]

66.

Avalle L, Camporeale A, Morciano G, Caroccia N, Ghetti E, Orecchia V, et al. STAT3 localizes to the ER, acting as a gatekeeper for ER-mitochondrion Ca²⁺ fluxes and apoptotic responses. Cell Death Differ. 2019;26:932–42. [DOI] [PubMed] [PMC]

67.

Kaiser U, Schilli M, Haag U, Neumann K, Kreipe H, Kogan E, et al. Expression of bcl-2--protein in small cell lung cancer. Lung Cancer. 1996;15:31–40. [DOI] [PubMed]

68.

Kønig SM, Rissler V, Terkelsen T, Lambrughi M, Papaleo E. Alterations of the interactome of Bcl-2 proteins in breast cancer at the transcriptional, mutational and structural level. PLoS Comput Biol. 2019;15:e1007485. [DOI] [PubMed] [PMC]

69.

Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995;55:237–41. [PubMed]

70.

Tao S, Gu J, Wang Q, Zheng L. Translational control of Bcl-2 promotes apoptosis of gastric carcinoma cells. BMC Cancer. 2021;21:12. [DOI] [PubMed] [PMC]

71.

Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, et al. BAX and BAK regulation of endoplasmic reticulum Ca²⁺: a control point for apoptosis. Science. 2003;300:135–9. [DOI] [PubMed]

72.

Chiu WT, Chang HA, Lin YH, Lin YS, Chang HT, Lin HH, et al. Bcl-2 regulates store-operated Ca²⁺ entry to modulate ER stress-induced apoptosis. Cell Death Discov. 2018;4:37. [DOI]

73.

Dremina ES, Sharov VS, Kumar K, Zaidi A, Michaelis EK, Schöneich C. Anti-apoptotic protein Bcl-2 interacts with and destabilizes the sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase (SERCA). Biochem J. 2004;383:361–70. [DOI] [PubMed] [PMC]

74.

Bergner A, Kellner J, Tufman A, Huber RM. Endoplasmic reticulum Ca²⁺-homeostasis is altered in small and non-small cell lung cancer cell lines. J Exp Clin Cancer Res. 2009;28:25. [DOI] [PubMed] [PMC]

75.

Luik RM, Wang B, Prakriya M, Wu MM, Lewis RS. Oligomerization of STIM1 couples ER calcium depletion to CRAC channel activation. Nature. 2008;454:538–42. [DOI] [PubMed] [PMC]

76.

Pierro C, Cook SJ, Foets TCF, Bootman MD, Roderick HL. Oncogenic K-Ras suppresses IP3-dependent Ca²⁺ release through remodelling of the isoform composition of IP3Rs and ER luminal Ca²⁺ levels in colorectal cancer cell lines. J Cell Sci. 2014;127:1607–19. [DOI] [PubMed]

77.

Dai Y, Jin S, Li X, Wang D. The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer. Oncotarget. 2017;8:1354–68. [DOI] [PubMed] [PMC]

78.

Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 2001;15:1406–18. [DOI] [PubMed] [PMC]

79.

Yanagawa N, Leduc C, Kohler D, Saieg MA, John T, Sykes J, et al. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. J Thorac Oncol. 2012;7:1513–21. [DOI] [PubMed]

80.

Bononi A, Bonora M, Marchi S, Missiroli S, Poletti F, Giorgi C, et al. Identification of PTEN at the ER and MAMs and its regulation of Ca²⁺ signaling and apoptosis in a protein phosphatase-dependent manner. Cell Death Differ. 2013;20:1631–43. [DOI] [PubMed] [PMC]

81.

Hsu PC, Jablons DM, Yang CT, You L. Epidermal growth factor receptor (EGFR) pathway, yes-associated protein (YAP) and the regulation of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC). Int J Mol Sci. 2019;20:3821. [DOI]

82.

Kuo HY, Chen YC, Chang HY, Jeng JC, Lin EH, Pan CM, et al. The PML isoform IV is a negative regulator of nuclear EGFR’s transcriptional activity in lung cancer. Carcinogenesis. 2013;34:1708–16. [DOI] [PubMed]

83.

Ko J, Winslow MM, Sage J. Mechanisms of small cell lung cancer metastasis. EMBO Mol Med. 2021;13:e13122. [DOI] [PubMed] [PMC]

84.

Isogai T, van der Kammen R, Leyton-Puig D, Kedziora KM, Jalink K, Innocenti M. Initiation of lamellipodia and ruffles involves cooperation between mDia1 and the Arp2/3 complex. J Cell Sci. 2015;128:3796–810. [DOI] [PubMed]

85.

Brundage RA, Fogarty KE, Tuft RA, Fay FS. Calcium gradients underlying polarization and chemotaxis of eosinophils. Science. 1991;254:703–6. [DOI] [PubMed]

86.

Giannone G, Rondé P, Gaire M, Beaudouin J, Haiech J, Ellenberg J, et al. Calcium rises locally trigger focal adhesion disassembly and enhance residency of focal adhesion kinase at focal adhesions. J Biol Chem. 2004;279:28715–23. [DOI] [PubMed]

87.

Webb DJ, Parsons JT, Horwitz AF. Adhesion assembly, disassembly and turnover in migrating cells--over and over and over again. Nat Cell Biol. 2002;4:E97–100. [DOI] [PubMed]

88.

Burnette DT, Manley S, Sengupta P, Sougrat R, Davidson MW, Kachar B, et al. A role for actin arcs in the leading-edge advance of migrating cells. Nat Cell Biol. 2011;13:371–81. [DOI] [PubMed] [PMC]

89.

Cortesio CL, Boateng LR, Piazza TM, Bennin DA, Huttenlocher A. Calpain-mediated proteolysis of paxillin negatively regulates focal adhesion dynamics and cell migration. J Biol Chem. 2011;286:9998–10006. [DOI] [PubMed] [PMC]

90.

Nobes CD, Hall A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol. 1999;144:1235–44. [DOI] [PubMed] [PMC]

91.

Tkachenko E, Sabouri-Ghomi M, Pertz O, Kim C, Gutierrez E, Machacek M, et al. Protein kinase A governs a RhoA-RhoGDI protrusion-retraction pacemaker in migrating cells. Nat Cell Biol. 2011;13:660–7. [DOI] [PubMed] [PMC]

92.

Tsai FC, Meyer T. Ca²⁺ pulses control local cycles of lamellipodia retraction and adhesion along the front of migrating cells. Curr Biol. 2012;22:837–42. [DOI] [PubMed] [PMC]

93.

Yang S, Huang XY. Ca²⁺ influx through L-type Ca²⁺ channels controls the trailing tail contraction in growth factor-induced fibroblast cell migration. J Biol Chem. 2005;280:27130–7. [DOI] [PubMed]

94.

Kim Y, Chang S. Modulation of actomyosin contractility by myosin light chain phosphorylation/dephosphorylation through Rho GTPases signaling specifies axon formation in neurons. Biochem Biophys Res Commun. 2004;318:579–87. [DOI] [PubMed]

95.

Giannone G, Dubin-Thaler BJ, Rossier O, Cai Y, Chaga O, Jiang G, et al. Lamellipodial actin mechanically links myosin activity with adhesion-site formation. Cell. 2007;128:561–75. [DOI] [PubMed] [PMC]

96.

Ofer N, Mogilner A, Keren K. Actin disassembly clock determines shape and speed of lamellipodial fragments. Proc Natl Acad Sci U S A. 2011;108:20394–9. [DOI] [PubMed] [PMC]

97.

Taylor CW, Taufiq-Ur-Rahman, Pantazaka E. Targeting and clustering of IP3 receptors: key determinants of spatially organized Ca²⁺ signals. Chaos. 2009;19:037102. [DOI] [PubMed]

98.

Pines G, Köstler WJ, Yarden Y. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett. 2010;584:2699–706. [DOI] [PubMed] [PMC]

99.

Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2008;14:2895–9. [DOI] [PubMed]

100.

Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9:52. [DOI]

101.

Tsai FC, Seki A, Yang HW, Hayer A, Carrasco S, Malmersjö S, et al. A polarized Ca²⁺, diacylglycerol and STIM1 signalling system regulates directed cell migration. Nat Cell Biol. 2014;16:133–44. [DOI] [PubMed] [PMC]

102.

Bartlett PJ, Cloete I, Sneyd J, Thomas AP. IP3-dependent Ca²⁺ oscillations switch into a dual oscillator mechanism in the presence of PLC-linked hormones. iScience. 2020;23:101062. [DOI] [PubMed] [PMC]

103.

Kiselyov K, Shin DM, Muallem S. Signalling specificity in GPCR-dependent Ca²⁺ signalling. Cell Signal. 2003;15:243–53. [DOI] [PubMed]

104.

Huertas MA, Smith GD. The dynamics of luminal depletion and the stochastic gating of Ca²⁺-activated Ca²⁺ channels and release sites. J Theor Biol. 2007;246:332–54. [DOI] [PubMed]

105.

Chantôme A, Potier-Cartereau M, Clarysse L, Fromont G, Marionneau-Lambot S, Guéguinou M, et al. Pivotal role of the lipid Raft SK3-Orai1 complex in human cancer cell migration and bone metastases. Cancer Res. 2013;73:4852–61. [DOI] [PubMed]

106.

White C. The regulation of tumor cell invasion and metastasis by endoplasmic reticulum-to-mitochondrial Ca²⁺ transfer. Front Oncol. 2017;7:171. [DOI] [PubMed] [PMC]

107.

Dreval V, Dieterich P, Stock C, Schwab A. The role of Ca²⁺ transport across the plasma membrane for cell migration. Cell Physiol Biochem. 2005;16:119–26. [DOI] [PubMed]

108.

Arbabian A, Brouland JP, Apáti Á, Pászty K, Hegedűs L, Enyedi Á, et al. Modulation of endoplasmic reticulum calcium pump expression during lung cancer cell differentiation. FEBS J. 2013;280:5408–18. [DOI] [PubMed]

109.

Coello MC, Luketich JD, Litle VR, Godfrey TE. Prognostic significance of micrometastasis in non-small-cell lung cancer. Clin Lung Cancer. 2004;5:214–25. [DOI] [PubMed]

110.

Roato I. Bone metastases: when and how lung cancer interacts with bone. World J Clin Oncol. 2014;5: 149–55. [DOI] [PubMed] [PMC]

111.

Oyewumi MO, Alazizi A, Wehrung D, Manochakian R, Safadi FF. Emerging lung cancer therapeutic targets based on the pathogenesis of bone metastases. Int J Cell Biol. 2014;2014:236246. [DOI] [PubMed] [PMC]

112.

Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11:411–25. [DOI] [PubMed] [PMC]

113.

Jung Y, Shiozawa Y, Wang J, Patel LR, Havens AM, Song J, et al. Annexin-2 is a regulator of stromal cell-derived factor-1/CXCL12 function in the hematopoietic stem cell endosteal niche. Exp Hematol. 2011;39:151–66.e1. [DOI] [PubMed] [PMC]

114.

Reid JC, Tanasijevic B, Golubeva D, Boyd AL, Porras DP, Collins TJ, et al. CXCL12/CXCR4 signaling enhances human PSC-derived hematopoietic progenitor function and overcomes early in vivo transplantation failure. Stem Cell Reports. 2018;10:1625–41. [DOI] [PubMed] [PMC]

115.

Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci. 2006;1092:385–96. [DOI] [PubMed]

116.

Ohgushi H. Osteogenically differentiated mesenchymal stem cells and ceramics for bone tissue engineering. Expert Opin Biol Ther. 2014;14:197–208. [DOI] [PubMed]

117.

Lerner UH, Kindstedt E, Lundberg P. The critical interplay between bone resorbing and bone forming cells. J Clin Periodontol. 2019;46 Suppl 21:33–51. [DOI] [PubMed]

118.

Kuchimaru T, Hoshino T, Aikawa T, Yasuda H, Kobayashi T, Kadonosono T, et al. Bone resorption facilitates osteoblastic bone metastatic colonization by cooperation of insulin-like growth factor and hypoxia. Cancer Sci. 2014;105:553–9. [DOI] [PubMed] [PMC]

119.

Dvorak-Ewell MM, Chen TH, Liang N, Garvey C, Liu B, Tu C, et al. Osteoblast extracellular Ca²⁺-sensing receptor regulates bone development, mineralization, and turnover. J Bone Miner Res. 2011;26:2935–47. [DOI] [PubMed] [PMC]

120.

Yoshida N, Sato T, Kobayashi K, Okada Y. High extracellular Ca²⁺ and Ca²⁺-sensing receptor agonists activate nonselective cation conductance in freshly isolated rat osteoclasts. Bone. 1998;22:495–501. [DOI] [PubMed]

121.

Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Butters RR, Brown EM. Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology. 2000;141:4357–64. [DOI] [PubMed]

122.

Wen L, Sun L, Xi Y, Chen X, Xing Y, Sun W, et al. Expression of calcium sensing receptor and E-cadherin correlated with survival of lung adenocarcinoma. Thorac Cancer. 2015;6:754–60. [DOI] [PubMed] [PMC]

123.

Song I, Kim JH, Kim K, Jin HM, Youn BU, Kim N. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. FEBS Letters. 2009;583:2435–40. [DOI] [PubMed]

124.

Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, Oyajobi BO, et al. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res. 2011;71:822–31. [DOI] [PubMed] [PMC]

125.

Smith AL, Robin TP, Ford HL. Molecular pathways: targeting the TGF-β pathway for cancer therapy. Clin Cancer Res. 2012;18:4514–21. [DOI] [PubMed]

126.

Gu S, Feng XH. TGF-β signaling in cancer. Acta Biochim Biophys Sin (Shanghai). 2018;50:941–9. [DOI] [PubMed]

127.

Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res. 2005;15:57–62. [DOI] [PubMed]

128.

Salcedo R, Oppenheim JJ. Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. Microcirculation. 2003;10:359–70. [DOI] [PubMed]

129.

Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem. 2008;283:4283–94. [DOI] [PubMed]

130.

Yang LL, Liu BC, Lu XY, Yan Y, Zhai YJ, Bao Q, et al. Inhibition of TRPC6 reduces non-small cell lung cancer cell proliferation and invasion. Oncotarget. 2017;8:5123–34. [DOI] [PubMed] [PMC]

131.

Jiang HN, Zeng B, Zhang Y, Daskoulidou N, Fan H, Qu JM, et al. Involvement of TRPC channels in lung cancer cell differentiation and the correlation analysis in human non-small cell lung cancer. PloS one. 2013;8:e67637. [DOI] [PubMed] [PMC]

132.

Khan I, Bahuguna A, Kumar P, Bajpai VK, Kang SC. In vitro and in vivo antitumor potential of carvacrol nanoemulsion against human lung adenocarcinoma A549 cells via mitochondrial mediated apoptosis. Sci Rep. 2018;8:144. [DOI] [PubMed] [PMC]

133.

Koparal AT, Zeytinoglu M. Effects of carvacrol on a human non-small cell lung cancer (NSCLC) cell line, A549. Cytotechnology. 2003;43:149–54. [DOI] [PubMed] [PMC]

134.

Lau JK, Brown KC, Dom AM, Witte TR, Thornhill BA, Crabtree CM, et al. Capsaicin induces apoptosis in human small cell lung cancer via the TRPV6 receptor and the calpain pathway. Apoptosis. 2014;19:1190–201. [DOI] [PubMed] [PMC]

135.

Milian L, Mata M, Alcacer J, Oliver M, Sancho-Tello M, Martín de Llano JJ, et al. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. PloS one. 2020;15:e0228909. [DOI] [PubMed] [PMC]

136.

Wang LJ, Li J, Hao FR, Yuan Y, Li JY, Lu W, et al. Dexamethasone suppresses the growth of human non-small cell lung cancer via inducing estrogen sulfotransferase and inactivating estrogen. Acta pharmacol Sin. 2016;37:845–56. [DOI] [PubMed] [PMC]

137.

Shin DH, Leem DG, Shin JS, Kim JI, Kim KT, Choi SY, et al. Compound K induced apoptosis via endoplasmic reticulum Ca²⁺ release through ryanodine receptor in human lung cancer cells. J Ginseng Res. 2018;42:165–74. [DOI] [PubMed] [PMC]

138.

Roussel E, Bélanger MM, Couet J. G2/M blockade by paclitaxel induces caveolin-1 expression in A549 lung cancer cells: caveolin-1 as a marker of cytotoxicity. Anticancer Drugs. 2004;15:961–7. [DOI] [PubMed]

139.

Choi SY, Yu JH, Kim H. Mechanism of alpha-lipoic acid-induced apoptosis of lung cancer cells. Ann N Y Acad Sci. 2009;1171:149–55. [DOI] [PubMed]

140.

Xu X, Chen D, Ye B, Zhong F, Chen G. Curcumin induces the apoptosis of non-small cell lung cancer cells through a calcium signaling pathway. Int J Mol Med. 2015;35:1610–6. [DOI] [PubMed]

141.

Wong BS, Chiu LY, Tu DG, Sheu GT, Chan TT. Anticancer effects of antihypertensive L-type calcium channel blockers on chemoresistant lung cancer cells via autophagy and apoptosis. Cancer Manag Res. 2020;12:1913–27. [DOI] [PubMed] [PMC]

142.

Hou XB, Li TH, Ren ZP, Liu Y. Combination of 2-deoxy d-glucose and metformin for synergistic inhibition of non-small cell lung cancer: a reactive oxygen species and P-p38 mediated mechanism. Biomed Pharmacother. 2016;84:1575–84. [DOI] [PubMed]

143.

Shteinfer-Kuzmine A, Amsalem Z, Arif T, Zooravlov A, Shoshan-Barmatz V. Selective induction of cancer cell death by VDAC1-based peptides and their potential use in cancer therapy. Mol Oncol. 2018;12:1077–103. [DOI] [PubMed] [PMC]